GlaxoSmithKline's Venture Arm Backs UK biotech Syntaxin

LONDON, Oct 31 (Reuters) - Syntaxin Ltd, a private biotech firm developing novel drugs that work by controlling cell secretion, has raised 16 million pounds ($33 million) in a new funding round co-led by SR One, the venture capital arm of GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research).

Back to news